What is GoldenExo® NCLU?

NCLU is a lyophilized UC-MSC extracellular vesicle raw material developed for inhalation, nebulization and respiratory formulation research.

Is the supplied 5 mL solution the only compatible diluent?

It is the standard companion presentation. Alternative buffers, excipients or device-specific formulations require compatibility and stability evaluation.

Can Echo Biotech test EV quality after nebulization?

Yes. A customized project may include particle recovery, size, integrity, marker, purity and functional testing before and after device delivery.

Is NCLU a finished inhalation drug?

No. NCLU is a research and further-manufacturing material, not an approved finished inhalation therapy.

GoldenExo® NCLU

A lyophilized UC-MSC extracellular vesicle presentation supplied with a 5 mL companion solution for nebulization, airway-delivery feasibility and respiratory formulation-development studies.

Quick Facts

MSC-EV Material for Inhalation / Nebulization Research
Particle Content: 2.0E+10 particles / vial
Presentation: Lyophilized + 5 mL solution
Storage: 2-8°C
Shipping: Ambient or ice-pack
Research Route: Inhalation / nebulization
COA
TDS
Nebulizer Compatibility
Airway Model Research

Connecting lyophilized EV material and companion solution to repeatable inhalation-formulation research.

NCLU is designed for project-level evaluation around nebulizer devices, airway deposition, respiratory microenvironment and formulation compatibility.

Route-Ready Presentation: Lyophilized EV material and companion solution support repeatable reconstitution and aerosol-formulation work.

Local-Delivery Research: Designed for studies exploring deposition in the airway and distal lung under controlled experimental conditions.

Respiratory Microenvironment Focus: Suitable for investigating inflammatory balance, epithelial support and repair-related responses.

Development Services: Nebulizer compatibility, aerosol characterization and formulation optimization can be incorporated into a custom project.

Evaluation pathway designed around product use

01 Source & Cell Bank: Confirm source, cell identity and batch traceability.

02 Culture & Harvest: Control culture system and harvest window by product positioning.

03 Purification & Concentration: Match purification strategy to lyophilized, frozen or formulation-development needs.

04 Fill & Storage: Define specification, packaging and shipping conditions.

05 Quality Evaluation: Combine EV identity, purity, safety and functional tests by project.

06 Application Support: Connect to formulation, delivery, model validation and co-development.

From EV Identity to Post-Nebulization Quality Retention

Source Identity & Traceability: Documented human UC-MSC or defined producer-cell sourcing; Cell-bank identity and batch records; Project-appropriate traceability and source controls

Controlled Manufacturing: Defined culture, harvest and purification workflows; Lyophilized or cryopreserved presentation by product design; Batch consistency and scale-up compatibility

Orthogonal Quality Evaluation: Particle concentration, size and EV identity; Purity, membrane integrity and safety tests; Functional or stability assays selected by project

Batch-Level Documentation: COA, TDS and SDS supplied by project scope; Connection to formulation development and further manufacturing; Support for technical review and collaboration planning

Product-specific analytical focus: Projects may evaluate particle recovery after reconstitution, post-nebulization size/integrity, markers, purity, sterility, endotoxin and functional readouts.

Where the Product Can Fit

Airway Delivery: Study local administration strategies for bronchial and pulmonary research models.

Mucosal and Epithelial Support: Evaluate cellular responses related to airway-barrier stress and recovery.

Inflammatory Microenvironment: Investigate modulation of respiratory inflammatory signaling in vitro and in vivo.

Aerosol Compatibility: Assess reconstitution, device loss, particle recovery and post-nebulization EV quality.

Key Information for Technical Evaluation

Product Name: GoldenExo® NCLU

Material Type: UC-MSC-derived extracellular vesicles / exosomes

Particle Content: 2.0E+10 particles / vial

Presentation: Lyophilized EV + 5 mL companion solution

Storage: 2-8°C

Shipping: Ambient or ice-pack

Research Route: Inhalation, nebulization and airway-delivery feasibility

Collaboration: Device compatibility, aerosol characterization, formulation optimization and model validation

The companion solution, nebulizer device and alternative buffers should be evaluated for compatibility and stability.

From Product Supply to Co-Development

Standard Material Supply: Deliver material and agreed documentation according to product specification.

Formulation & Delivery Development: Evaluate concentration, excipients, packaging and application format.

Quality & Stability Research: Extend analytics, stability and model validation by project.

OEM / ODM / CDMO: Connect raw material, prototype and further manufacturing collaboration.

FAQ

What is GoldenExo® NCLU?: NCLU is a lyophilized UC-MSC extracellular vesicle raw material developed for inhalation, nebulization and respiratory formulation research.
Is the supplied 5 mL solution the only compatible diluent?: It is the standard companion presentation. Alternative buffers, excipients or device-specific formulations require compatibility and stability evaluation.
Can Echo Biotech test EV quality after nebulization?: Yes. A customized project may include particle recovery, size, integrity, marker, purity and functional testing before and after device delivery.
Is NCLU a finished inhalation drug?: No. NCLU is a research and further-manufacturing material, not an approved finished inhalation therapy.